Kent and Medway Medical School
28 imported, source-linked research records. Published in the last five years.
28 matching research records
Only records linked to Kent and Medway Medical School are included. Historical ingestion is still running; these are imported records, not a count of all research worldwide.
Showing 1–28 of 28 matching records. Counts update as records arrive.
Rheological characterisation and printability assessment of an optimised bioink for extrusion-based 3D bioprinting
June 1, 2026 · 0 citations · Open access
Open original record →Remote, lower-intensity, multidomain lifestyle intervention for subjective cognitive decline or mild cognitive impairment (APPLE-Tree): a multicentre, single-masked, randomised controlled trial
October 1, 2025 · 10 citations · Open access
Open original record →Utilising design of experiment to design an optimised bioink for 3D bioprinting
June 20, 2025 · 7 citations · Open access
Open original record →Designing a primary care pharmacist-led review for people treated with opioids for persistent pain: a multi-method qualitative study
April 17, 2024 · 5 citations · Open access
Open original record →Advancements and progress in juvenile idiopathic arthritis: A Review of pathophysiology and treatment
March 29, 2024 · 18 citations · Open access
Open original record →Genetic Associations of Lipid-Lowering Drugs and Parkinson’s Disease: A Mendelian Randomization Study
January 16, 2024 · 0 citations · Open access
Open original record →New-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I, DPP4I and GLP1a: A population-based cohort study
November 27, 2023 · 2 citations · Open access
Open original record →Compare SGLT2I versus non-SGLT2I users in type-2 diabetic mellitus patients on GLP-1 receptor agonist: A population-based and machine learning causal inference analysis
November 7, 2023 · 2 citations · Open access
Open original record →Clinical and Non-Clinical Cardiovascular Disease Associated Pathologies in Parkinson’s Disease
August 9, 2023 · 12 citations · Open access
Open original record →Comparing the risks of new-onset gastric cancer or gastric diseases in type 2 diabetes mellitus patients exposed to SGLT2I, DPP4I or GLP1A: a population-based cohort study
July 5, 2023 · 0 citations · Open access
Open original record →Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
May 6, 2023 · 37 citations · Open access
Open original record →Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
March 31, 2023 · 24 citations · Open access
Open original record →Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin‐induced myocardial injury
March 30, 2023 · 20 citations · Open access
Open original record →Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity score-matched study with competing risk analysis
February 19, 2023 · 0 citations · Open access
Open original record →Association of proteinuria and risk of incident atrial fibrillation in the general population: A prospective study of Kailuan study participants
January 13, 2023 · 3 citations · Open access
Open original record →Population-Based Clinical Studies Using Routinely Collected Data in Hong Kong, China: A Systematic Review of Trends and Established Local Practices
January 1, 2023 · 16 citations · Open access
Open original record →Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched study with competing risk analysis
October 29, 2022 · 20 citations · Open access
Open original record →Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity score-matched study
October 1, 2022 · 2 citations · Open access
Open original record →Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
September 6, 2022 · 38 citations
Open original record →Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study
September 5, 2022 · 6 citations · Open access
Open original record →Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study
August 17, 2022 · 5 citations · Open access
Open original record →Association between leucocyte telomere length and the risk of atrial fibrillation: An updated systematic review and meta-analysis
August 3, 2022 · 32 citations · Open access
Open original record →Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study
July 22, 2022 · 3 citations · Open access
Open original record →Lower Risks of Incident Colorectal Cancer in SGLT2i Users Compared to DPP4i Users: A Propensity Score-matched Study with Competing Risk Analysis
July 18, 2022 · 1 citations · Open access
Open original record →Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study
June 1, 2022 · 26 citations · Open access
Open original record →Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
February 10, 2022 · 48 citations · Open access
Open original record →Incident Heart Failure and Myocardial Infarction in Sodium-Glucose Cotransporter-2 vs. Dipeptidyl Peptidase-4 Inhibitor Users
February 7, 2022 · 28 citations · Open access
Open original record →Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
October 21, 2021 · 112 citations · Open access
Open original record →